William BASc - NervGen Pharma CoFounder Chairman
| NGEN Stock | CAD 2.87 0.08 2.87% |
Chairman
William BASc is CoFounder Chairman of NervGen Pharma Corp
| Age | 61 |
| Address | 112-970 Burrard Street, Vancouver, BC, Canada, V6Z 2R4 |
| Phone | 778 731 1711 |
| Web | https://www.nervgen.com |
NervGen Pharma Management Efficiency
The company has return on total asset (ROA) of (0.5314) % which means that it has lost $0.5314 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.3027) %, meaning that it generated substantial loss on money invested by shareholders. NervGen Pharma's management efficiency ratios could be used to measure how well NervGen Pharma manages its routine affairs as well as how well it operates its assets and liabilities. At this time, NervGen Pharma's Return On Capital Employed is fairly stable compared to the past year. Return On Equity is likely to climb to 11.70 in 2024, whereas Return On Tangible Assets are likely to drop (1.85) in 2024. Intangibles To Total Assets is likely to climb to 0.07 in 2024, whereas Total Assets are likely to drop slightly above 11.3 M in 2024.Similar Executives
| Found 4 records | CHAIRMAN Age | ||
| Bradford LCA | Microsoft Corp CDR | 65 | |
| Jeffrey Bezos | Amazon CDR | 60 | |
| Warren Buffett | Berkshire Hathaway CDR | 94 | |
| Charles Munger | Berkshire Hathaway CDR | 100 | |
Management Performance
| Return On Equity | -2.3 | ||||
| Return On Asset | -0.53 |
NervGen Pharma Corp Leadership Team
Elected by the shareholders, the NervGen Pharma's board of directors comprises two types of representatives: NervGen Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NervGen. The board's role is to monitor NervGen Pharma's management team and ensure that shareholders' interests are well served. NervGen Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NervGen Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Brian McAlister, CoFounder Advisor | ||
| Harold DMD, CoFounder Director | ||
| Elizabeth BSc, Senior Management | ||
| Michael Kelly, President CEO | ||
| Adam MD, Interim Director | ||
| Charles DSc, Senior Operations | ||
| William BASc, CoFounder Chairman |
NervGen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NervGen Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.3 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | 180.91 M | ||||
| Shares Outstanding | 70.31 M | ||||
| Shares Owned By Insiders | 22.91 % | ||||
| Shares Owned By Institutions | 0.06 % | ||||
| Number Of Shares Shorted | 199.54 K | ||||
| Price To Book | 21.99 X | ||||
| EBITDA | (19.24 M) | ||||
| Net Income | (22.38 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NervGen Stock Analysis
When running NervGen Pharma's price analysis, check to measure NervGen Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NervGen Pharma is operating at the current time. Most of NervGen Pharma's value examination focuses on studying past and present price action to predict the probability of NervGen Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NervGen Pharma's price. Additionally, you may evaluate how the addition of NervGen Pharma to your portfolios can decrease your overall portfolio volatility.